Opus Genetics (IRD) Interest & Investment Income (2010 - 2020)
Opus Genetics (IRD) posted quarterly Interest & Investment Income of $1774.0 for Q3 2020, down 97.74% year-over-year from $78534.0 in Q4 2019, and down 70.64% quarter-over-quarter from $6042.0 in Q2 2020.
Opus Genetics (IRD) Interest & Investment Income (2010 - 2020) Analysis & Trends
Opus Genetics (IRD) has reported Interest & Investment Income for 11 consecutive years, with $1774.0 the latest figure, recorded in Q3 2020.
- In Q3 2020, Interest & Investment Income fell 97.74% year-over-year to $1774.0; the TTM figure through Sep 2020 stood at $99365.0 (down 68.21% YoY), while the FY2019 annual figure was $313700.0, up 23.34% from the prior year.
- Interest & Investment Income slipped to $1774.0 in Q3 2020 per IRD's latest filing, from $6042.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $96650.0 in Q2 2019 and bottomed at $1774.0 in Q3 2020.
- Historically, Interest & Investment Income has averaged $49255.1 across 5 years, with a median of $55153.0 in 2018.
- Annual changes were most pronounced in 2018 — Interest & Investment Income surged 138.19% — and 2020, when it tumbled 97.74%.
- Opus Genetics' Interest & Investment Income stood at $34681.0 in 2016, then soared by 106.67% to $71674.0 in 2017, then dropped by 21.89% to $55982.0 in 2018, then increased by 2.05% to $57131.0 in 2019, then sank by 96.89% to $1774.0 in 2020.
- Business Quant data shows IRD's Interest & Investment Income at $1774.0 in Q3 2020, $6042.0 in Q2 2020, and $34418.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 1,774.00 |
| Jun 30, 2020 | 6,042.00 |
| Mar 31, 2020 | 34,418.00 |
| Dec 31, 2019 | 57,131.00 |
| Sep 30, 2019 | 78,534.00 |
| Jun 30, 2019 | 96,650.00 |
| Mar 31, 2019 | 81,385.00 |
| Dec 31, 2018 | 55,982.00 |
| Sep 30, 2018 | 55,153.00 |
| Jun 30, 2018 | 67,473.00 |
| Mar 31, 2018 | 75,736.00 |
| Dec 31, 2017 | 71,674.00 |
| Sep 30, 2017 | 60,750.00 |
| Jun 30, 2017 | 42,782.00 |
| Mar 31, 2017 | 31,797.00 |
| Dec 31, 2016 | 34,681.00 |
| Sep 30, 2016 | 26,145.00 |
| Jun 30, 2016 | 28,868.00 |
| Mar 31, 2016 | 28,871.00 |
| Dec 31, 2015 | 21,943.00 |